- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03269058
Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (Cinétique DAPA)
February 22, 2024 updated by: Centre Hospitalier Universitaire Dijon
Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes
This study will make it possible to better understand the mechanisms responsible for the increase in bad cholesterol levels observed in patients with type 2 diabetes treated with Dapagliflozin, an antidiabetic treatment made by Astrazeneca.
The information will:
- reveal what is not working properly
- make it possible to choose the most appropriate treatments against cholesterol to compensate for this impaired functioning
This biomedical research will take place at the University Hospitals of DIJON and NANTES.
- 28 patients will take part: 20 patients will be given Dapagliflozin and 8 patients will be given the placebo.
- The study treatment will be randomised: patients will be given either Dapagliflozin or the placebo. The treatment duration is 6 months.
- Moreover, during the inclusion visit and at the end of the study (6 months after the start of treatment), a kinetics study, to follow the production and elimination of cholesterol, will be conducted. This will involve administering amino acids that have been specifically synthesised for this purpose.
- Participation in the study will last 6 months and include 4 protocol visits.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21079
- CHU Dijon Bourgogne
-
Nantes, France, 44093
- CHU de Nantes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- persons who have provided written consent
- type 2 diabetes treated with OAD (metformin and/or sulfonylurea and/or glinides and/or acarbose and/or DPPIV inhibitors)
- Stable treatment for 3 months
- HbA1c between 7.5% and 10%
- Age between 30 and 65 years
- BMI between 25 and 35 kg/m²
- Triglycerides < 300 mg/dl
- Half of the patients being treated with statins
- eGFR > 75 ml/min/1.73 m² at inclusion
Exclusion Criteria:
- persons without national health insurance cover
- patients treated with Insulin or a GLP-1 agonist
- Patients under guardianship
- patients treated with lipid-lowering drugs (except statins for 50% of patients)
- kidney failure
- liver failure or abnormal liver function ASAT or ALAT >3 x upper limit of normal
- total bilirubin >2mg/dl
- intestinal disease
- serological evidence of an active liver infection (surface antigen of hepatitis B, hepatitis C antibodies, hepatitis B IgM antibodies)
- Pregnancy, breastfeeding
- hypersensitivity to the active substance or to excipients
- patients with volume depletion, for example due to an acute disease (gastro-intestinal disease)
- patients treated with loop diuretics or thiazides
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients not treated with statins
|
Dapagliflozin 10 mg daily per os
Placebo of Dapagliflozin per day per os
|
Experimental: Patients treated with statins
|
Dapagliflozin 10 mg daily per os
Placebo of Dapagliflozin per day per os
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline the rate of production of VLDL Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the rate of production of IDL Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the rate of production of LDL Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the rate of production of HDL Apo A1
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the Fractional Catabolic Rate of VLDL1 Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the Fractional Catabolic Rate of VLDL2 Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the Fractional Catabolic Rate of IDL Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the Fractional Catabolic Rate of LDL Apo B
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Change from baseline the Fractional Catabolic Rate of HDL 'Apo A1
Time Frame: 15 days before treatment initiation, Day 0, Day 90 and Day 180
|
15 days before treatment initiation, Day 0, Day 90 and Day 180
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2017
Primary Completion (Actual)
May 6, 2021
Study Completion (Actual)
May 6, 2021
Study Registration Dates
First Submitted
August 25, 2017
First Submitted That Met QC Criteria
August 30, 2017
First Posted (Actual)
August 31, 2017
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VERGES AZ 2015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type-2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Dapagliflozin
-
AstraZenecaRecruitingHeart Failure and Impaired Kidney FunctionSpain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Brazil, Finland, Greece, Israel, Mexico, United Kingdom, Turkey, Colombia, Slov... and more
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaRecruitingLiver CirrhosisDenmark, Spain, Germany, United States, France, Australia, China, Belgium, Netherlands, Switzerland, Austria, United Kingdom, Taiwan, Canada, Czechia
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands